Trabectedin or doxorubicin for STS: Which has better outcomes?
Better clinical effects and longer survival time were noted in patients with soft-tissue sarcoma (STS) treated with trabectedin compared with those treated with doxorubicin, according to new research.
A literature review of 10 studies on the use of trabectedin and doxorubicin in STS was evaluated.
Overall, patients treated with trabectedin had longer progression-free survival than those receiving doxorubicin [overall mean difference (MD) =1.36, 95% confidence interval (CI): 1.04, 1.68, I2=6%, fixed-effects model]. In addition, patients in the experimental group had a longer overall survival time and a better disease control rate than patients in the control group.
Reference
Dang J, Fu J, Zhang Z, et al. Comparison between trabectedin and doxorubicin in soft-tissue sarcomas: a systematic review and meta-analysis. Ann Transl Med. 2021;9(24):1764. doi: 10.21037/atm-21-6033. PMID: 35071458; PMCID: PMC8756232.
